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ABSTRACT
The psychological burden experienced by people with diabetes prior to islet transplantation is
recognized but has not been studied comprehensively, especially in relation to glycemia. Therefore,
we conducted a rigorous pre-operative psychosocial profile of UK islet transplant recipients, and
compared groups with higher/lower HbA1 c to test the null hypothesis that pre-transplant hypogly-
cemia awareness and psychosocial burden would not be related to baseline HbA1 c in this high-risk
cohort. Pre-transplant, recipients (n = 44) completed validated hypoglycemia awareness question-
naires and generic/diabetes-specific measures of psychological traits and states. Scores were com-
pared in groups, dichotomized by HbA1 c (≤8% versus >8%). Participants were aged (mean±SD)
53 ± 10 years; 64%werewomen; withHbA1 c 8.3 ± 1.7%.Median rate of severe hypoglycemia over the
preceding 12 months was 13 events/person-year and 90% had impaired awareness of hypoglycemia
(Gold/Clarke score ≥4). Participants had elevated fear of hypoglycemia (HFS-II Worry), impaired
diabetes-specific quality of life (DQoL) and low generic health status (SF-36; EQ-5D). One quarter
reported scores indicating likely anxiety/depression (HAD). Dispositional optimism (LOT-R) and gen-
eralized self-efficacy (GSE) were within published ‘norms.’ Despite negative perceptions of diabetes
(including low personal control), participants were confident that islet transplantation would help
(BIPQ). Hypoglycemia awareness and psychosocial profile were comparable in lower (n = 24) and
higher (n = 20) HbA1 c groups. Islet transplant candidates report sub-optimal generic psychological
states (anxiety/depressive symptoms), health status and diabetes-specific psychological states (fear of
hypoglycemia, diabetes-specific quality of life). While their generic psychological traits (optimism, self-
efficacy) are comparable with the general population, they are highly optimistic about forthcoming
transplant. HbA1 c is not a proxy measure of psychosocial burden, which requires the use of validated
questionnaires to systematically identify those who may benefit most from psychological assessment
and support.
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Introduction
Following seminal success with the Edmonton
protocol, insulin independence was established as
the principal goal for islet transplantation.1
Edmonton’s success has been replicated interna-
tionally but sustained insulin independence for
more than 3 years cannot be achieved in more
than 50% of recipients.2 In the UK, islet transplan-
tation is established as a fully reimbursed, equita-
bly available intervention, where the goal is
resolution of recurrent severe hypoglycemia (i.e.,
requiring the assistance of another person for
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recovery)3 and not insulin independence per se.
This has been demonstrated alongside improved
awareness of hypoglycemia and attainment of
optimal HbA1 c (<7%).3
Simple assessment of severe hypoglycemia fre-
quency and HbA1 c does not illuminate an indivi-
dual’s experience of living with diabetes. The potential
impact of islet transplant on psychological outcomes
(for better or worse) has been emphasized.4–10
Therefore, it is important that pre-transplant psycho-
social experience is taken into consideration.
Increasingly, patient-reported outcomes (PROs) are
considered alongside biomedical outcomes as part of
holistic transplant assessment. However, a systematic
review showed that PRO assessment in potential islet
transplantation recipients has been limited largely to
the appraisal of generic health status and/or fear of
hypoglycemia.4 Few studies have conducted
a rigorous assessment of psychological burden in
this high-risk cohort. The most comprehensive to
date found impaired generic mental health status
and depressive symptoms, alongside high fear of
hypoglycemia and elevated diabetes distress.11 These
factors may predict adaptation to life post-transplant,
including the need for lifelong immunosuppression
medication.12 Furthermore, psychological traits, such
as dispositional optimism and general self-efficacy,
which may also be of consequence, have not been
assessed previously in an islet transplantation
population.
The inverse relationship between HbA1 c and
severe hypoglycemia reported in the landmark
Diabetes Control and Complications Trial13 appears
to have driven a belief that sufficiently problematic/
frequent severe hypoglycemia to justify islet trans-
plantation occurs only in those with lower HbA1 c.
Conversely, it is often considered that suboptimal
psychological well-being is only experienced in
those with higher HbA1 c. Yet, severe hypoglycemia
is associated with considerable psychological
burden,14,15 and recent real-world clinical data
demonstrate that severe hypoglycemia occurs in
adults with type 1 diabetes regardless of their
HbA1 c level.14,16
The primary aim of this study was to character-
ize the pre-transplant self-reported psychological
and health burden experienced by recipients in the
UK program. We hypothesized that pre-transplant
hypoglycemia awareness and psychological burden
would not be related to baseline HbA1 c in this
high-risk cohort and, therefore, compared those
with higher (>8%) and lower (≤8%) HbA1 c at
listing for transplantation.17
Results
Forty-four consecutive participants consenting to
this study completed questionnaires on completion
of pre-transplant assessment and activation on the
waiting list. All subsequently received one or more
islet transplant (70 islet transplants in total). Table 2
summarizes the demographic and clinical charac-
teristics of participants. Sixty-four percent were
women. Mean±SD age was 53 ± 10 years, with
diabetes duration 34 ± 12 years, BMI
24.9 ± 3.4 kg/m2 and HbA1 c 8.3 ± 1.7%
(67 ± 18 mmol/mol). All had experienced at least
two severe hypoglycemia events over the preceding
2 years, fulfilling listing criteria. Within the preced-
ing 12 months, 90% had experienced at least one
severe hypoglycemic event, with 55% reporting ≥11
events, and 90% reported impaired awareness of
hypoglycemia (Gold and/or Clarke score ≥4).
When demographic and clinical characteristics
were compared in the group with higher HbA1 c
(>8%: n = 20) versus those with lower HbA1 c
(≤8%: n = 24) at listing for transplant, no signifi-
cant differences were found in severe hypoglyce-
mia rate or other baseline parameters, except
a trend toward longer diabetes duration in the
lower HbA1 c group (≤8%: 38 ± 12 vs >8%:
30 ± 9 years; p = .028).
Psychosocial outcomes are summarized for the
whole cohort and stratified by higher and lower
HbA1 c in Table 3. Mean±SD HFS-II Worry score
in the overall cohort was 45 ± 15, indicating high
fear of hypoglycemia. Mean DQOL subscale scores
for Satisfaction, Impact and Diabetes Worry ran-
ged from 47 to 57, indicating impaired diabetes-
specific quality of life; while the Social Worry scale
had considerable missing data.
Regarding diabetes perceptions (Table 3), study
participants reported very high ‘Concern’ about their
diabetes and its impact on their lives (‘Consequences’).
They perceived that diabetes would ‘continue forever’
(‘Timeline’) and reported a negative emotional burden
‘making them angry, scared, upset or depressed’
(‘Emotional representation’). Mid-range scores for
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‘experiencing symptoms from your diabetes’ were
reported (‘Identity’). While participants reported
understanding their diabetes ‘clearly’ (‘Coherence’),
they felt little ‘Personal control’ over their condition.
However, participants believed resoundingly that
a transplant would ‘help their diabetes’ (‘Transplant
control’).
Almost half reported clinically relevant (at least
mild) depression symptoms (HAD-D ≥ 8: 47%) and/
or anxiety symptoms (HAD-A ≥ 8: 49%). SF-36
Summary scores indicated substantial impairment
across Mental and Physical components. For the
EQ-5D, more than two-thirds reported (some/
extreme) problems in Usual Activities and Pain/
Discomfort, half reported (some/extreme) problems
with Anxiety/Depressive symptoms and Mobility,
while one in five had problems with Self-care.
For general psychological traits, the LOT-R and
GSES scores indicated that dispositional optimism
and generalized self-efficacy were comparable with
published norms for the UK general adult
population.18-20
Impaired awareness of hypoglycemia was com-
parable in those with higher and lower HbA1 c
(Table 3). No significant differences were observed
between the two HbA1 c groups for diabetes-specific
or generic psychosocial measures, with the exception
of a trend toward greater anxiety in those with higher
HbA1 c (p = .032). There were no significant differ-
ences in self-reported health status for the EQ-5D
domains or SF-36 Summary scores.
Discussion
This study provides the most comprehensive psy-
chosocial characterization to date of adults with
type 1 diabetes undergoing islet transplantation. It
demonstrates that the self-reported psychological
and health burden before the procedure is not
trivial, with many reporting considerable psycho-
logical distress associated with recurrent danger-
ous hypoglycemia and long disease duration.
Despite problematic hypoglycemia being the
major indication for islet transplantation candi-
dacy, fear of hypoglycemia has been assessed in
only four previous studies.6,8,10,21 In the current
study, we used the HFS-II, but others have used
the original HFS, or used an alternate scoring
method for the HFS-II, such that scores are not
directly comparable between islet transplantation
studies. In the current cohort, mean HFS-II Worry
score was twice that of the US validation sample
comprising a wide range of individuals with estab-
lished type 1 diabetes,22 and comparable with or
higher than studies in which participants have
reported at least one severe hypoglycemic event
within the past 6 months.14,17 Norms and cut-
points to define clinically relevant elevation in
fear of hypoglycemia have been established for
the HFS-II in adults with type 223 but not type 1
diabetes; however, higher scores indicate greater
fear and are typically found among those with
most frequent and severe hypoglycemia.22 Listing
for islet transplantation in those with recurrent
severe hypoglycemia and impaired awareness of
hypoglycemia is thus associated with significant
pre-transplant fear of hypoglycemia.
Diabetes-specific quality of life was assessed
with the DQOL questionnaire in order to enable
comparisons with previous islet transplantation
studies.4 Scores suggested lower diabetes-specific
quality of life in prospective UK recipients than
observed at baseline in other published islet trans-
plant studies,7,9 and also in a UK study of adults
with type 1 diabetes,24 reflecting the high burden
of living with diabetes in the current cohort. These
findings are consistent with an in-depth, qualita-
tive study of islet transplant candidates, which
demonstrated a high pre-operative psychological
burden, predominantly from recurrent, unpredict-
able severe hypoglycemia, with considerable nega-
tive impact on quality of life.5
At the point of joining the islet transplantation
waiting list, questionnaire screening indicative of
‘caseness’ for anxiety and depression was detected
in one quarter and one-fifth of the participants,
respectively. The HAD scale can offer only an indi-
cator of symptom severity, which requires confirma-
tion with a clinical diagnostic interview. While these
rates appear concerning, they are similar to those
reported in epidemiological studies and meta-
analyses of the general type 1 diabetes
population.25-27 For example, these pre-transplant
rates are highly comparable with those observed in
a large cohort (n = 639) – 24% had ‘caseness’ for
anxiety and 21% for depression – prior to attending
a UK structured type 1 diabetes education
program.28 Importantly, it has been noted elsewhere
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that questionnaire-based scores of generic anxiety/
depression show moderate-to-strong correlations
with diabetes-related distress.23
The Brief Illness Perceptions Questionnaire has
not previously been completed by prospective islet
transplant recipients. This confirmed how severely
life is affected by diabetes in this select, high-risk
cohort, leading to a high level of concern and
considerable emotional impact. Participants felt
little control over their diabetes, and perceived
that islet transplantation would be extremely help-
ful. Despite being on the islet transplant list they
had a clear perception that their diabetes would
continue forever. It was notable, however, in the
preceding qualitative study, that UK islet trans-
plant recipients hoped for at least ‘a break from
diabetes.’5 They reported realistic expectations,
having being counseled that long-term insulin
independence was not a goal, but many retained
‘hidden hopes of being among the minority to
remain insulin free.’
While participants reported a high level of con-
fidence that the transplant would help their diabetes,
their general dispositional optimismwas comparable
to the general UK adult population18,19 and some-
what lower than that of Dutch adults with type 1
diabetes.29 Generalized self-efficacy levels among the
current islet transplantation recipients were also
comparable with the general UK adult population20
and with Dutch adults with type 1 diabetes.29 Many
studies have highlighted the positive health benefits
of an optimistic outlook, though these have tended
to focus on outcomes of cardiovascular disease and
cancer. A previous qualitative study of islet trans-
plant candidates demonstrated that they were willing
to accept the potential risks associated with trans-
plantation and ongoing immunosuppression.5
Psychological traits, such as dispositional optimism
and general self-efficacy, were also shown to be
important for how participants dealt with the uncer-
tainty of ‘life on the list’ for a transplant.5 This is the
first islet transplantation cohort in which these psy-
chological traits have been assessed quantitatively.
Given that islet transplantation involves accepting,
adapting and coping with the procedure and its
consequences, it will be of interest to note in future
studies, whether high expectations for transplanta-
tion (which may or may not be realized) and/or
more generally optimistic beliefs impact upon
biomedical outcomes and quality of life following
islet transplantation.
Previous studies of conventional non-transplant
intervention for severe hypoglycemia17 have
dichotomized participants into groups with
HbA1 c ≤ 8% (to capture those with a strong
primary motivation to avoid all high glucose
excursions) and >8% (characterized by higher glu-
cose variability) and we agreed on a priori to
dichotomize the current pre-islet transplant cohort
using this HbA1 c value. HbA1 c was >8% in just
under half of those studied. All fulfilled the listing
criteria of recurrent severe hypoglycemia with
comparable impaired awareness of hypoglycemia
and fear of hypoglycemia scores to those with
lower HbA1 c. All diabetes and generic psychoso-
cial scores in this highly selected cohort were very
similar in higher and lower HbA1 c groups, with
the exception of a trend toward greater anxiety in
those with higher HbA1 c, consistent with studies
in a wider spectrum of adults with type 1
diabetes.30 This underlines the negative psycholo-
gical impact and burden of severe hypoglycemia
and impaired awareness of hypoglycemia, irre-
spective of baseline HbA1 c.
This study has several clinical implications.
Clinicians need to be aware that individuals listed
for islet transplantation are characterized by the
considerable psychological burden and impact of
their problematic hypoglycemia on well-being and
quality of life; and that this is irrespective of
whether baseline HbA1 c is in a higher or lower
range. Furthermore, individuals considering islet
transplantation exhibit high levels of confidence
that the procedure can alleviate this burden,
despite having only an averagely optimistic dispo-
sition in comparison to the wider population. As
noted previously, these high expectations need to
be recognized by transplant teams, and strategies
considered for how best to support the individual
in coping with disappointments at any stage.5
Since its inception, the UK national program has
included provision for psychological assessment of
suitability for islet transplantation, mandated as
part of the multidisciplinary team decision for
inclusion on the waiting list.31 The Diabetes UK
patient guide ‘Islet Cell Transplant: What You
Need to Know’ indicates that a meeting with
a clinical psychologist will be arranged to
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determine whether ‘extra psychological support
during or after the procedure’ may be needed.32
In addition to ruling out major psychological/psy-
chiatric co-morbidity, a particular focus is on
assessing the individual’s level of understanding
of the potential risks as well as benefits of islet
transplantation, and determining whether they
have realistic expectations. It is not clear whether
expert psychological evaluation is embedded
within other programs internationally.33
Informed by the current study, we recommend
formal-structured psychological assessment of all
potential islet transplant recipients, to include eva-
luation of fear of hypoglycemia, diabetes-specific
quality of life, anxiety/depressive symptoms and
perceptions/expectations of the procedure. This
will enable identification and follow-up of indivi-
dualized psychological needs pre- and post-
transplantation, facilitating provision of evidence-
based support and intervention as required. This
should augment adoption of the evidence-
informed clinical pathways, which have been pro-
posed in recent years to guide the therapeutic
strategies offered to those with problematic hypo-
glycemia, including those under assessment for or
awaiting islet transplant.34 The absence of statisti-
cally significant differences in psychosocial ques-
tionnaire outcomes between those with higher
versus lower pre-transplant HbA1 c further under-
lines the importance of holistic assessment of all
potential islet recipients using validated tools and
approaches, in parallel with baseline biomedical
evaluation.
The current study has several strengths. It is
a multi-center, multi-disciplinary study, recruiting
a cohort of patients within the first national health
service funded program of islet transplantation as
an established clinical intervention for prevention
of severe hypoglycemia and achievement of
HbA1 c < 7%. It is the largest and most compre-
hensive study to date of the psychosocial charac-
terization of adults undergoing islet
transplantation. Furthermore, this study used vali-
dated generic and diabetes-specific psychological
measures to characterize both psychological traits
and states. This study also has several limitations,
including a relatively small sample compared with
non-islet transplant studies. There is no control
group, as it was designed as a cohort study. We
have not reported data on diabetes-related com-
plications beyond confirmation of satisfactory
renal function through serum creatinine. Despite
few missing data overall, the completion rate for
DQOL Social Worry subscale was very low, in
keeping with the previously observed low face
validity of this section of the questionnaire for an
adult cohort.35
In summary, we have conducted detailed base-
line profiling of a relatively large islet transplant
cohort. Overall, these adults with long-standing
type 1 diabetes exhibit considerable diabetes-
specific psychological burden (i.e., lower dia-
betes-specific quality of life, greater fear of hypo-
glycemia and equivalent anxiety/depressive
symptoms) compared with the wider adult popu-
lation with type 1 diabetes in the UK. Their
psychological traits (e.g., optimistic beliefs) are
comparable to the general population, though
they exhibit extremely high levels of confidence
in the ability of islet transplantation to help with
their diabetes. Furthermore, this study highlights
that HbA1 c is not a proxy measure for under-
lying psychological burden. Comprehensive dia-
betes-specific psychosocial evaluation needs to be
integral to the multidisciplinary assessment of
whether islet transplantation will be suitable for
an individual with type 1 diabetes; and ongoing
psychosocial support will be needed throughout
the transplant process.
Patients and methods
The integrated UK Islet Transplant Consortium
(UKITC) program comprises seven National
Health Service commissioned centers: Bristol,
Edinburgh, King’s College London, Royal Free
London, Manchester, Newcastle and Oxford.
Following ethical approval from the NRES
Committee North East – Tyne and Wear South
(REC reference 07/Q0904/11) and informed writ-
ten consent, a prospective cohort of consecutive
individuals were recruited fulfilling all consensus
inclusion criteria for islet transplantation without
exclusion criteria (Table 1). In parallel with pre-
listing biomedical assessment, all were invited to
complete psychological measures at the point of
joining the transplant waiting list between
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April 2008 and March 2011. All subsequently
received one or more islet transplant(s).
Demographic and clinical data included HbA1 c
and number of self-reported severe hypoglycemia
events over the preceding 12 months.36
A comprehensive set of psychological characteris-
tics and outcomes were assessed, as described
below.
Hypoglycemia awareness
The Gold Score37 is a single question (“do you
know when your hypos are commencing?”) rated
on a 7-point Likert scale, from 1 = ‘always aware’
to 7 = ‘never aware.’ The eight-item Clarke
Questionnaire38 assesses occurrence of moderate
and severe hypoglycemia, and experience of
hypoglycemic symptoms. Responses to each ques-
tion are categorized as either ‘aware’ or ‘reduced
awareness.’ For both the Gold score and the Clarke
questionnaire, a score of ≥4 indicates impaired
awareness of hypoglycemia.
Fear of hypoglycemia
The Hypoglycemia Fear Survey-II (HFS-II)39
includes 33 statements, rated in terms of how
often each has been a concern in the last 6 months,
from 0 = ‘never’ to 4 = ’almost always.’ Eighteen
item scores are summed to create a ‘worry’ score
(range: 0–72), where higher scores indicate greater
worry about hypoglycemia and its negative conse-
quences. Fifteen item scores are summed to form
a ‘behaviour’ score (range: 0–60), where higher
scores indicate increased behavior to avoid hypo-
glycemia and its negative consequences.
Diabetes-specific quality of life
The Diabetes Quality Of Life questionnaire
(DQOL)40 includes 46 items across four subscales:
‘life satisfaction’ (15 items), ‘diabetes impact’ (20
items), ‘worries about diabetes’ (4 items), and
‘social/vocational concerns’ (7 items). All items are
scored on a 5-point Likert scale (from 1 (‘very satis-
fied,’ ‘no impact, or ‘no worry’) to 5 (‘very dissatis-
fied,’ ‘always impacted,’ or ‘always worried’)).
Subscale scores are calculated by taking the sum of
items (reversing scores as needed) and converting
this raw total to a score out of 100. Higher scores
indicate better diabetes-specific quality of life.
Perceptions of diabetes
The Brief Illness Perceptions Questionnaire
(BIPQ)41 includes eight items, each one assessing
a different dimension (e.g., perceived control,
emotional impact). Each item is rated on an 11-
point scale (from 0 to 10), where higher scores
indicate greater endorsement of that dimension.
According to convention, the questionnaire was
made condition-specific for the current study, by
replacing ‘illness’ with ‘diabetes,’ and replacing
‘treatment’ with ‘transplant.’ For item 3 (‘How
much control, do you have over your diabetes?’)
and item 7 (‘How well do you feel you understand
Table 1. Inclusion and exclusion criteria for the UK islet trans-
plant program
Inclusion criteria Exclusion criteria
● Age: ≥18 years
● Diagnosis: C-peptide-negative
diabetes
● History: recurrent severe
hypoglycemia (at least two
events over the preceding
24 months requiring assistance
from another person to
administer carbohydrate,
glucagon or other resuscitative
actions36) despite optimized
conventional management
● Insulin resistance (insulin
requirement >0.7 U/kg)
● Any contraindication to
immunosuppression, including
impaired renal function with
isotopic GFR<60 mL/min/
1.73 m2 or albumin excretion
rate >300 mg/24 h (unless
previous renal transplant)
Table 2. Demographic and clinical characteristics of islet trans-
plant recipients (n = 44)
Gender, woman 28 (64%)
Age, years 53.1 ± 10.0
Diabetes duration, years 34.4 ± 11.5
BMI, kg/m2 24.9 ± 3.4
HbA1 c, %
mmol/mol
8.3 ± 1.7
67 ± 18
Insulin dose, Units/kg/day 0.52 ± 0.19
Creatinine, µmol/l 89.8 ± 36.2
Severe hypoglycemia, events per person-
year
● 0
● 1
● 2–4
● 5–10
● 11–20
● 21–50
● >50
13.0 (3.5–51.0)
[0–51.0]
4 (10.0%)
2 (5.0%)
5 (12.5%)
7 (17.5%)
5 (12.5%)
5 (12.5%)
12 (20.0%)
Data are n (%) or, depending on distribution, mean±SD or median
(IQR) [range].
Missing datapoints were apparent for creatinine (n = 42) and severe
hypoglycemia (n = 40).
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your diabetes?’), higher scores indicate more
positive perceptions of diabetes. Item 4 is the
only treatment-specific question (‘How much do
you think your transplant can help your dia-
betes?’), with higher scores referring to a more
positive perception. For all other items, higher
scores indicate more negative perception of dia-
betes impact.
Anxiety and depressive symptoms
The Hospital Anxiety and Depression (HAD)
scale42 includes two 7-item subscales: ‘anxiety’
and ‘depression.’ Respondents rate items using
a 4-point scale (from 0 to 3). Item scores are
summed to form subscale scores (from 0 to 21),
with higher scores indicating greater anxiety or
Table 3. Pre-transplant psychosocial characteristics, for whole sample and stratified by HbA1c
Diabetes-specific psychosocial states n Whole sample
HbA1c
p-Valuen
≤8%
(n = 24) n
>8%
(n = 20)
Hypoglycemia awareness
● Gold score (1–7)
● Clarke questionnaire (0–7)
30
30
6.0 (6.0–7.0) [1–7]
6.0 (5.0–7.0) [1–7]
17
16
7.0 (6.0–7.0)
5.5 (5.0–7.0)
13
14
6.0 (6.0–7.0)
6.0 (6.0–7.0)
.234 b
.644 b
Fear of hypoglycemia
● HFS-II Worry (0–72)
● HFS-II Behavior (0–60)
40
39
45.2 ± 15.3
34.4 ± 13.3
21
22
45.7 ± 15.4
31.0 ± 14.4
19
17
44.8 ± 15.4
38.9 ± 10.6
.867 a
.066 a
Diabetes-specific quality of life (0–100)
● DQoL Satisfaction
● DQoL Impact
● DQoL Social Worry
● DQoL Diabetes Worry
43
42
8
44
56.8 ± 16.8
51.7 ± 13.3
75.6 ± 15.7
47.3 ± 22.0
23
23
5
24
59.8 ± 17.4
53.5 ± 13.3
83.2 ± 13.2
47.7 ± 18.1
20
19
3
20
53.3 ± 15.8
49.6 ± 13.4
62.9 ± 11.3
47.0 ± 26.5
.206 a
.359 a
.069 a
.921 a
Perceptions of diabetes (0–10)
● BIPQ Consequences
● BIPQ Timeline
● BIPQ Personal control
● BIPQ Transplant control
● BIPQ Identity
● BIPQ Illness concern
● BIPQ Coherence
● BIPQ Emotional representation
43
43
43
42
41
42
42
44
9 (8–10) [4–10]
10 (10–10) [0–10]
3 (1–6) [0–10]
10 (8–10) [7–10]
8 (4–9) [0–10]
10 (9–10) [3–10]
10 (8–10) [0–10]
8 (5.5–10) [0–10]
23
24
24
23
23
24
23
24
9.0 (8.0–10)
10.0 (10–10)
4.0 (0.25–8.0)
10 (8.0–10.0)
8.0 (5.0–10)
10.0 (8.5–10)
10 (9.0–10)
8.0 (5.0–9.5)
20
19
19
19
18
18
19
20
8.5 (7.5–10.0)
10 (10–10)
3.0 (1.0–6.0)
10 (8.0–10)
6.5 (1.0–9.0)
10 (9.0–10)
9.0 (8–10)
8.5 (7.5–10)
.543 b
.732 b
.413 a
.852 b
.158 b
1.000 b
.298 b
.290 b
Generic psychosocial states and traits
Anxiety symptoms: HAD-A (0–21)
● HAD-A ≥ 8
● HAD-A ≥ 11 (‘caseness’)
Depressive symptoms: HAD-D (0–21)
● HAD-D ≥ 8
● HAD-D ≥ 11 (‘caseness’)
43
21
11
43
20
9
7.9 ± 4.9
21 (48.8)
11 (26.6)
6.9 ± 4.4
20 (46.5)
9 (20.9)
23
9
2
23
11
5
6.4 ± 4.6
9 (39.1)
2 (8.7)
6.1 ± 4.4
11 (47.8)
5 (21.7)
20
12
9
20
9
4
9.6 ± 4.8
12 (60.0)
9 (45.0)
7.8 ± 4.4
9 (45.0)
4 (20.0)
.032 a
.221 a
Dispositional optimism: LOT-R (0–24) 44 11.8 ± 4.4 24 12.2 ± 5.0 20 11.3 ± 3.7 .500 a
Generalized self-sfficacy: GSES (10–40) 42 29.2 ± 4.6 22 30.4 ± 4.8 20 27.9 ± 3.9 .080 a
Generic health status
SF-36v2 Summary scores (0–100)
● Mental component
● Physical component
41
41
40.0 ± 13.7
43.0 ± 8.2
22
22
43.2 ± 12.9
43.8 ± 7.7
19
19
36.3 ± 14.1
42.0 ± 8.8
.110 a
.486 a
EQ-5D-3 L (% with some/extreme problems)
● Mobility
● Self-care
● Usual activities
● Pain/discomfort
● Anxiety/depression
41
42
42
42
41
22 (53.7%)
9 (21.4%)
29 (69.0%)
29 (69.1%)
24 (55.8%)
23
23
23
23
22
11 (47.8%)
3 (13.0%)
17 (73.9%)
15 (65.2%)
12 (54.5%)
18
19
19
19
19
11 (61.1%)
6 (31.6%)
12 (63.2%)
14 (73.7%)
12 (63.2%)
.397 c
.257 d
.453 c
.555 c
.577 c
Data are n (%) or, depending on distribution, mean±SD or median (IQR) [range]. Differences analyzed using aStudent’s t-test, bMann-Whitney
U test, cChi-square test or dFisher’s exact test.
For each measure the potential range is shown in the left-hand column next to the name of the measure or subscale. Higher scores Gold and Clarke
Score indicate likely impaired awareness of hypoglycemia. Higher scores on the HFS-II indicate increased worry about, and behavior to avoid
hypoglycemia and its negative consequences. Higher scores on the DQOL indicate better diabetes-specific quality of life, while higher scores on
the SF-36 indicate better general physical or mental health status. Higher scores on the BIPQ indicate greater endorsement of the named
dimension (perception of diabetes). Higher HAD scores indicate greater anxiety or depression symptomatology. Higher scores on the LOT-R
indicate a greater disposition toward optimism. Higher GSES scores indicates greater confidence in one’s capacity for coping.
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depression symptomatology. A score of ≥8 indi-
cates at least mild anxiety or depression symptoms
(borderline ‘caseness’), while a score of ≥11, indi-
cating moderate-to-severe symptoms, is regarded
as ‘caseness.’42
Optimistic beliefs
Outcome expectancies were measured with the Life
Orientation Test –Revised [LOT-R],43 which includes
10 statements rated on a 5-point Likert scale, where
0 = ‘strongly agree’ and 4 = ‘strongly disagree.’ The
three pessimism item scores are reversed and added to
the three optimism item scores, while four ‘filler’ items
are ignored. Total scores range from 0 to 24, with
higher scores indicating a greater disposition toward
optimism. Participants also completed the
Generalized Self-Efficacy Scale (GSES)44 includes 10
statements rated on a 4-point scale, where 1 = ‘not at
all true’ and 4 = ‘exactly true.’ Item scores are summed
to create a total score ranging from 10 to 40, with
higher scores indicating greater confidence in one’s
capacity for coping.
Generic health status
The SF-36v245 is a 36-item questionnaire that yields
two summary scores: Physical Component Score and
Mental Component Score (each ranging from 0 to
100). Participants also completed the EQ-5D-3 L46
tariff, which comprises five items or dimensions of
general health rated using three response options (‘no
problems,’ ‘some problems,’ ‘extreme problems’). For
the current study, we report the proportion of parti-
cipants experiencing ‘some/extreme problems’ for
each dimension. For both SF-36 and EQ-5D, higher
scores indicate better general health status and lower
scores indicate more health limitations.
Statistical analyses were conducted using STATA
statistical package version 14.1 (StataCorp, Texas,
USA). For all psychological measures, missing data
were handled with expectation-maximization impu-
tation for up to 10% missing data, unless the ques-
tionnaire guidelines stated otherwise. For the DQOL,
subscale scores were not computed if respondents had
more missing data than deemed acceptable in the
scoring guideline.40 Categorical data were expressed
as n (%). Continuous data were expressed as mean ±
standard deviation (SD) or median (interquartile
range) [range] as appropriate to the data distribution.
Demographic, clinical and psychological outcomes
were compared in participants with higher (>8%),
and lower (≤8%) HbA1c.17 Comparisons were con-
ducted using Student’s t-test for parametric data and
Mann-Whitney U test for non-parametric data.
Categorical variables were compared using the Chi-
square test, or Fisher’s exact when the expected values
in any of the cells of a contingency table are below 5,
or below 10 when there is only one degree of freedom.
Given the number of statistical tests, and the explora-
tory nature of the analysis, significance was set
at p < .01.
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